Comparison of N-acetyltransferase-2 enzyme genotype-phenotype and xanthine oxidase enzyme activity between Swedes and Koreans

Journal of Clinical Pharmacology

Volumn 52, Issue 10, 2012, Pages 1527-1534

  Djordjevic, Natasa ^a,b   Carrillo, Juan Antonio ^c   Roh, Hyung Keun ^d   Karlsson, Sara ^a   Ueda, Nobuhisa ^a   Bertilsson, Leif ^a   Aklillu, Eleni ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF KRAGUJEVAC   (Serbia)

^c UNIVERSITY OF EXTREMADURA   (Spain)

^d Gachon University   (South Korea)

Author keywords

Koreans; NAT2; Swedes; XO

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CAFFEINE; ORAL CONTRACEPTIVE AGENT; XANTHINE OXIDASE;

ADULT; AGE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME POLYMORPHISM; ETHNIC DIFFERENCE; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; KOREA; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; SEX DIFFERENCE; SMOKING; SWEDEN;

ARYLAMINE N-ACETYLTRANSFERASE; ASIAN CONTINENTAL ANCESTRY GROUP; CAFFEINE; CONTRACEPTIVES, ORAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HUMANS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEX FACTORS; URACIL; URIC ACID; XANTHINE OXIDASE; XANTHINES;

EID: 84870455236     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011420261     Document Type: Article

References (37)

1. Guerciolini R, Szumlanski C, Weinshilboum RM. Human liver xanthine oxidase: nature and extent of individual variation. Clin Pharmacol Ther. 1991 ; 50: 663-672
2. Pritsos CA. Cellular distribution, metabolism and regulation of the xanthine oxidoreductase enzyme system. Chem Biol Interact. 2000 ; 129: 195-208
3. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006 ; 58: 87-114
4. Jetter A, Kinzig M, Rodamer M, et al. Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?. Eur J Clin Pharmacol. 2009 ; 65 (4). 411-417
5. Kudo M, Moteki T, Sasaki T, et al. Functional characterization of human xanthine oxidase allelic variants. Pharmacogenet Genomics. 2008 ; 18: 243-251
6. Harrison R. Structure and function of xanthine oxidoreductase: where are we now?. Free Radic Biol Med. 2002 ; 33: 774-797
7. Aklillu E, Carrillo JA, Makonnen E, Bertilsson L, Ingelman-Sundberg M. Xanthine oxidase activity is influenced by environmental factors in Ethiopians. Eur J Clin Pharmacol. 2003 ; 59: 533-536
8. Begas E, Kouvaras E, Tsakalof A, Papakosta S, Asprodini EK. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. Biomed Chromatogr. 2007 ; 21: 190-200
9. Relling MV, Lin JS, Ayers GD, Evans WE. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther. 1992 ; 52: 643-658
10. Meisel P. Arylamine N-acetyltransferases and drug response. Pharmacogenomics. 2002 ; 3: 349-366
11. Gross M, Kruisselbrink T, Anderson K, et al. Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol Biomarkers Prev. 1999 ; 8: 683-692
12. Westwood IM, Kawamura A, Fullam E, et al. Structure and mechanism of arylamine N-acetyltransferases. Curr Top Med Chem. 2006 ; 6: 1641-1654
13. Boukouvala S, Fakis G. Arylamine N-acetyltransferases: what we learn from genes and genomes. Drug Metab Rev. 2005 ; 37: 511-564
14. Saruwatari J, Nakagawa K, Shindo J, et al. A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test. Clin Pharmacol Ther. 2002 ; 72: 200-208
15. Okkels H, Sigsgaard T, Wolf H, Autrup H. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol Biomarkers Prev. 1997 ; 6: 225-231
16. Wood AJ. Ethnic differences in drug disposition and response. Ther Drug Monit. 1998 ; 20: 525-526
17. Muscat JE, Pittman B, Kleinman W, et al. Comparison of CYP1A2 and NAT2 phenotypes between black and white smokers. Biochem Pharmacol. 2008 ; 76: 929-937
18. Evans DA. N-acetyltransferase. Pharmacol Ther. 1989 ; 42: 157-234
19. Ghotbi R, Christensen M, Roh HK, et al. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype- phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol. 2007 ; 63: 537-546
20. Carrillo JA, Christensen M, Ramos SI, et al. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. Ther Drug Monit. 2000 ; 22: 409-417
21. Anitha A, Banerjee M. Arylamine N-acetyltransferase 2 polymorphism in the ethnic populations of South India. Int J Mol Med. 2003 ; 11: 125-131
22. Djordjevic N, Carrillo JA, Ueda N, et al. N-acetyltransferase-2 (NAT2) gene polymorphisms and enzyme activity in Serbs: unprecedented high prevalence of rapid acetylators in a white population. J Clin Pharmacol. :
23. Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther. 1991 ; 50: 508-519
24. Rasmussen BB, Brosen K. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Ther Drug Monit. 1996 ; 18: 254-262
25. Djordjevic N, Carrillo JA, Gervasini G, Jankovic S, Aklillu E. In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population. Eur J Clin Pharmacol. 2010 ; 66: 571-578
26. Chung WG, Kang JH, Park CS, Cho MH, Cha YN. Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism. Clin Pharmacol Ther. 2000 ; 67: 258-266
27. Brown AM, Benboubetra M, Ellison M, et al. Molecular activation- deactivation of xanthine oxidase in human milk. Biochim Biophys Acta. 1995 ; 1245: 248-254
28. Miners JO, Birkett DJ. The use of caffeine as a metabolic probe for human drug metabolizing enzymes. Gen Pharmacol. 1996 ; 27: 245-249
29. Cascorbi I, Drakoulis N, Brockmoller J, et al. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet. 1995 ; 57: 581-592
30. Le Marchand L, Sivaraman L, Franke AA, et al. Predictors of N-acetyltransferase activity: should caffeine phenotyping and NAT2 genotyping be used interchangeably in epidemiological studies?. Cancer Epidemiol Biomarkers Prev. 1996 ; 5: 449-455
31. Pompeo F, Brooke E, Kawamura A, Mushtaq A, Sim E. The pharmacogenetics of NAT: structural aspects. Pharmacogenomics. 2002 ; 3: 19-30
32. Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol. 2003 ; 59: 303-312
33. Kang TS, Jin SK, Lee JE, Woo SW, Roh J. Comparison of genetic polymorphisms of the NAT2 gene between Korean and four other ethnic groups. J Clin Pharm Ther. 2009 ; 34: 709-718
34. Lee S, Lee K, Ki C, et al. Complete sequencing of a genetic polymorphism in NAT2 in the Korean population. Clin Chem. 2002 ; 48: 775-777
35. Hein DW. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res. 2002 ; 506-507: 65-77
36. Straka RJ, Burkhardt T, Lang NP, Hadsall KZ, Tsai MY. Discordance between N-acetyltransferase 2 phenotype and genotype in a population of Hmong subjects. J Clin Pharmacol. 2006 ; 46: 802-811
37. Ghotbi R, Gomez A, Milani L, et al. Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. Pharmacogenomics J. 2009 ; 9: 208-217